^
Association details:
| Biomarker: | GemPred signature |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1297P - Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial
Published date:
09/05/2022
Excerpt:
In the GEM arm, GemPred+ patients (n = 50, 30%) had a significantly longer disease-free survival (DFS) than GemPred- patients (n = 117, 70%)(median 27 vs 10 months, HR=0.43; 95%CI [0.29-0.65] p<0.001) and overall survival (OS) (median 68 vs 29 months, HR=0.42; 95%CI [0.27-0.66] p<0.001)....The statistical interaction between GEM and GemPred+ status was significant for DFS (HR=0.44; 95%CI [0.24-0.80]; p=0.008) and OS (HR 0.37; 95%CI [0.19-0.74] p=0.004)....The GemPred signature was positive in a quarter of patients and was associated with a similar survival in the gemcitabine adjuvant group compared to mFFX.
Trial ID:
